Payment overview · 2025
General Payments
$1,792.71
95 reported records · 28 companies
Healthcare provider profile · identity verified
Anton Christopher Daniel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEWPORT, TN · NPI 1700856135
Verified facts
What the public records show
CMS Open Payments records show Anton Christopher Daniel, MD received $1,792.71 in general payments during 2025 across 95 reported records.
Amgen Inc. accounted for 10.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 647 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 940 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 647 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 940 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $195.51 | 10.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.89 | 8.8% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $150.05 | 8.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $143.67 | 8.0% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $112.03 | 6.2% | 6 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $111.44 | 6.2% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $94.29 | 5.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.10 | 4.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.54 | 4.1% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $63.67 | 3.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $63.35 | 3.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $62.38 | 3.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.76 | 3.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.67 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.88 | 2.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $41.81 | 2.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $37.12 | 2.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $34.69 | 1.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.57 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.01 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.16 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.35 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.09 | 1.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.46 | 1.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.84 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.71 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.35 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.32 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,792.71 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $195.51 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $195.51 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $156.89 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $150.05 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $143.67 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $142.91 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $112.03 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $110.67 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $94.29 | 4 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $93.18 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $77.37 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $63.99 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $63.35 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.88 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $41.47 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| General - Male SUI Normalized: general male sui |
Device | Boston Scientific Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 940 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 647 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
647 | 54 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
940 | 66 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
647 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
940 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1070 | 101 |
| Eliquis | Apixaban | 940 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 685 | 111 |
| Jardiance | Empagliflozin | 647 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 95 |
| Gabapentin | Gabapentin | 535 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 505 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 456 | 94 |
| Losartan Potassium | Losartan Potassium | 393 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 67 |
| Donepezil Hcl | Donepezil Hcl | 361 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 315 | 40 |
| Simvastatin | Simvastatin | 276 | 13 |
| Furosemide | Furosemide | 274 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 267 | 33 |
| Lisinopril | Lisinopril | 249 | 39 |
| Montelukast Sodium | Montelukast Sodium | 216 | 28 |
| Carvedilol | Carvedilol | 215 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 43 |
| Repatha Sureclick | Evolocumab | 190 | 26 |
| Allopurinol | Allopurinol | 189 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 189 | 25 |
| Trazodone Hcl | Trazodone Hcl | 188 | 34 |
| Nebivolol Hcl | Nebivolol Hcl | 187 | 38 |
| Bumetanide | Bumetanide | 185 | 23 |
| Omeprazole | Omeprazole | 182 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 174 | 15 |
| Potassium Chloride | Potassium Chloride | 174 | 40 |
| Famotidine | Famotidine | 173 | 13 |
| Sertraline Hcl | Sertraline Hcl | 172 | 32 |
| Xtampza Er | Oxycodone Myristate | 159 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 158 | 14 |
| Metformin Hcl | Metformin Hcl | 156 | 26 |
| Myrbetriq | Mirabegron | 156 | suppressed |
| Ezetimibe | Ezetimibe | 152 | 36 |
| Xarelto | Rivaroxaban | 151 | 12 |
| Alendronate Sodium | Alendronate Sodium | 144 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 142 | 31 |
| Buspirone Hcl | Buspirone Hcl | 140 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 47 |
| Farxiga | Dapagliflozin Propanediol | 131 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 22 |
| Mirtazapine | Mirtazapine | 116 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 34 |
| Levetiracetam | Levetiracetam | 110 | 12 |
| Meloxicam | Meloxicam | 110 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 13 |
| Baclofen | Baclofen | 106 | suppressed |
| Mounjaro | Tirzepatide | 105 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 101 | suppressed |
| Torsemide | Torsemide | 100 | 17 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 95 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 11 |
| Alprazolam | Alprazolam | 90 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | suppressed |
| Lactulose | Lactulose | 87 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 86 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 35 |
| Ozempic | Semaglutide | 83 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 13 |
| Entresto | Sacubitril/Valsartan | 78 | 11 |
| Kerendia | Finerenone | 78 | 13 |
| Memantine Hcl | Memantine Hcl | 77 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 75 | 24 |
| Risperidone | Risperidone | 73 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 72 | suppressed |
| Linzess | Linaclotide | 71 | 21 |
| Tramadol Hcl | Tramadol Hcl | 71 | 13 |
| Lovastatin | Lovastatin | 67 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 67 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 14 |
| Colchicine | Colchicine | 64 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Terazosin Hcl | Terazosin Hcl | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 19 |
| Promethazine Hcl | Promethazine Hcl | 61 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 13 |
| Chlorthalidone | Chlorthalidone | 59 | 12 |
| Trulicity | Dulaglutide | 59 | 12 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 56 | 15 |
| Clonidine Hcl | Clonidine Hcl | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Metformin Hcl Er | Metformin Hcl | 55 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 12 |
| Cilostazol | Cilostazol | 53 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 53 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 52 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 51 | suppressed |
| Lorazepam | Lorazepam | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | suppressed |
| Finasteride | Finasteride | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Vraylar | Cariprazine Hcl | 44 | suppressed |
| Sotalol | Sotalol Hcl | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Indapamide | Indapamide | 42 | 14 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 12 |
| Edarbi | Azilsartan Medoxomil | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 35 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | suppressed |
| Prednisone | Prednisone | 32 | 16 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Carbidopa | Carbidopa | 22 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Dapsone | Dapsone | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 13 |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | 11 |
| Prolia | Denosumab | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,792.71 · 95 records | Amgen Inc. | AREXVY, Auvelity, Belbuca, Briviact, CAMZYOS, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, GEMTESA, GVOKE HYPOPEN, General - Male SUI, HETLIOZ, IBSRELA, INSPIRE, JARDIANCE, JOURNAVX, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, Nayzilam, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, WATCHMAN Access System, XTAMPZA, YUPELRI, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error